Rigel (RIGL) AI Stock Analysis

• Market Cap: $756.55M
• Dividend Yield: N/A
• Average Volume (3M): 625.49K
• Price to Earnings (P/E): 7.1
• Beta (1Y): 1.93
• Revenue Growth: 79.13%
• EPS Growth: 2798.12%
• Country: US
• Employees: 162
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.46
• Shares Outstanding: 18,151,344
• 10 Day Avg. Volume: 776,407
• 30 Day Avg. Volume: 625,488
• PEG Ratio: -0.10
• Price to Book (P/B): 89.93
• Price to Sales (P/S): 1.65
• P/FCF Ratio: 9.41
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 1.65
• Enterprise Value/Gross Profit: 1.78
• Enterprise Value/Ebitda: 3.75
• 1Y Price Target: $45.67
• Price Target Upside: 4.17% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 5.57
• Revenue Forecast (FY): $281.09M

• Rating: 77 Outperform
• Price Target: $52.00 ▲(18.61% Upside)

Rigel Pharmaceuticals demonstrates strong financial performance and positive earnings call sentiment, driving its overall score. The stock's undervaluation adds to its appeal, although technical indicators suggest caution due to overbought conditions. The absence of corporate events and a dividend yield slightly tempers the score.

Positive Factors

Revenue Growth

The significant year-over-year revenue growth indicates strong demand for Rigel's products, supporting long-term business expansion and market penetration.

Pipeline Advancements

Advancements in the R289 study and strategic collaborations enhance Rigel's pipeline, potentially leading to new product approvals and market opportunities.

Profitability and Cash Flow

Strong profitability and increased cash reserves provide Rigel with financial stability and flexibility to invest in future growth initiatives.

Negative Factors

Moderate Balance Sheet

While leverage is manageable, the moderate balance sheet and low equity ratio could pose risks if asset values decline, impacting financial stability.

Termination of CNS Program

The termination of the CNS program may limit Rigel's diversification in therapeutic areas, potentially affecting future growth opportunities.

Equity Position

A stronger equity position would enhance Rigel's financial resilience, reducing reliance on debt and improving long-term financial health.

Rigel Business Overview & Revenue Model

Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

How the Company Makes Money

Rigel Pharmaceuticals generates revenue through several key streams, primarily from the commercialization of its approved therapies. The company earns money by selling its marketed drugs, which include treatments for specific hematologic conditions. Additionally, Rigel may receive milestone payments and royalties from partnerships with larger pharmaceutical companies that involve co-development or licensing agreements for its drug candidates. Research and development collaborations also contribute to its revenue, allowing Rigel to leverage its technology and expertise while sharing costs and risks with partners. The success of its clinical trials and the subsequent approval of new therapies are critical factors influencing its earnings potential.

Rigel Financial Statement Overview

Summary

Rigel demonstrates strong profitability with high margins and consistent revenue growth. The balance sheet is moderate with manageable leverage, but could benefit from a stronger equity position. Cash flow is solid, supporting earnings efficiently.

Income Statement

Rigel's income statement shows strong profitability with a high gross profit margin of 93.10% and a net profit margin of 40.17% in the TTM period. The company has demonstrated consistent revenue growth, with a 5.28% increase in the latest TTM period. EBIT and EBITDA margins are also robust at 32.76% and 43.47%, respectively, indicating efficient cost management and operational performance.

Balance Sheet

The balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.52, suggesting manageable leverage. The return on equity is 4.39%, indicating decent profitability relative to shareholder equity. However, the equity ratio is relatively low, highlighting potential risks if asset values decline.

Cash Flow

Cash flow analysis reveals positive trends with a 3.01% growth in free cash flow. The operating cash flow to net income ratio is 0.72, indicating that a significant portion of net income is supported by cash flow. The free cash flow to net income ratio is nearly 1, showing efficient conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	282.08M	179.28M	116.88M	120.24M	149.24M	108.62M
Gross Profit	262.62M	160.63M	109.77M	118.49M	148.15M	107.73M
EBITDA	124.33M	28.51M	-16.98M	-53.87M	-11.29M	-27.68M
Net Income	113.30M	17.48M	-25.09M	-58.57M	-17.91M	-29.74M
Balance Sheet
Total Assets	242.53M	163.98M	117.22M	134.28M	167.33M	110.38M
Cash, Cash Equivalents and Short-Term Investments	137.14M	77.32M	56.93M	58.21M	124.97M	57.33M
Total Debt	60.88M	59.97M	60.58M	41.55M	30.57M	39.09M
Total Liabilities	124.92M	160.69M	145.87M	147.90M	136.95M	76.35M
Stockholders Equity	117.61M	3.29M	-28.64M	-13.62M	30.37M	34.03M
Cash Flow
Free Cash Flow	68.14M	31.07M	-20.74M	-74.21M	5.25M	-53.45M
Operating Cash Flow	68.18M	31.47M	-5.74M	-73.76M	5.88M	-52.19M
Investing Cash Flow	-77.92M	4.13M	-4.30M	72.78M	-80.04M	47.47M
Financing Cash Flow	6.64M	-11.64M	18.37M	6.55M	62.67M	12.57M

Rigel Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RIGL, the sentiment is Positive. The current price of 43.84 is above the 20-day moving average (MA) of 35.93, above the 50-day MA of 32.65, and above the 200-day MA of 25.30, indicating a bullish trend. The MACD of 3.44 indicates Negative momentum. The RSI at 65.97 is Neutral, neither overbought nor oversold. The STOCH value of 77.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RIGL.

Rigel Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	77 Outperform	$756.55M	7.11	220.06%	―	79.13%	2798.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LXRX	51 Neutral	$483.32M	-3.99	-45.92%	―	1255.21%	74.58%
RGNX	51 Neutral	$553.31M	―	-76.88%	―	91.30%	30.69%
VSTM	44 Neutral	$619.01M	―	-2888.70%	―	33.79%	-26.37%
BCYC	41 Neutral	$433.17M	―	-34.63%	―	-23.43%	-9.84%
OPT	39 Underperform	$477.76M	-3.01	―	―	-80.09%	60.14%

Rigel Corporate Events

Rigel Pharmaceuticals Reports Record Q3 Revenue and Growth

Rigel Pharmaceuticals’ recent earnings call reflected a robust financial performance, marked by substantial revenue growth and promising advancements in their drug development pipeline. Despite a setback with the termination of a CNS program by Eli Lilly, the overall sentiment was optimistic, focusing on the company’s growth and future expansion opportunities.

Rigel Pharmaceuticals Reports Strong Q3 2025 Results

Rigel Pharmaceuticals, Inc., a biotechnology company based in South San Francisco, focuses on developing therapies for hematologic disorders and cancer. The company is known for its innovative approach in the biotechnology sector, particularly in the treatment of immune thrombocytopenia and acute myeloid leukemia.

Eli Lilly and Rigel’s Promising Study on Rheumatoid Arthritis Treatment

Eli Lilly and Company, in collaboration with Rigel Pharmaceuticals, is conducting an adaptive Phase 2a/2b study titled ‘An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis.’ The study aims to evaluate the efficacy and safety of LY3871801 in treating adults with active moderate-to-severe rheumatoid arthritis, a condition that significantly impacts quality of life.